The Johnson & Johnson COVID-19 vaccine has little effect against the omicron variant according to a newly released study.
The report, which has not been peer reviewed yet, showed that the Johnson & Johnson shot — as well as China’s Sinopharm and Russia’s Sputnik V vaccines ¬— had no neutralizing activity against the new variant.
While the vaccines from Moderna, Pfizer and AstraZenca were better at fighting the omicron variant, they still showed a decrease in effectiveness compared to the original COVID strain, according to the study which was conducted by Humabs Biomed SA, a unit of Vir Biotechnology, and the University of Washington.
The study also showed that people who were previously infected by COVID-19 had a less robust immune response to omicron than to other variants.
The release of the study comes after the Advisory Committee on Immunization Practices for the Centers for Disease Control and Prevention announced on Thursday that they recommend adults select either the Pfizer or Moderna vaccines over the Johnson & Johnson shot to get vaccinated against COVID.